Request Copyright Permission

It’s All About Delivery: Pre-Clinical Development of a Surfactant Powder Aerosol Product

Hindle M, Farkas DR, DiBlasi RM, Momin M, KenKnight H, Hall F, Dalton CJ, Xu Q, Pangeni R, Aladwani G, Strickler S, Longest P.

Respiratory Drug Delivery 2025. Volume 1, 2025: 1-7.

Abstract:

Neonatal Respiratory Distress Syndrome (RDS) remains a leading cause of infant morbidity and mortality, particularly in preterm infants who lack sufficient pulmonary surfactant. Current treatment involves invasive administration of animal-derived liquid surfactant, which, despite being lifesaving, carries significant risks and is often inaccessible in low-resource settings. This work presents the development of a novel dry powder surfactant aerosol designed for non-invasive delivery, targeting the alveolar region with high efficiency and minimal equipment. The lead formulation, composed of synthetic phospholipids, is engineered for delivery via a low-flow air-jet inhaler suitable for fragile neonatal lungs. Pharmaceutical stability, dispersibility, and in vivo performance data support the feasibility of this approach as a transformative solution for global neonatal care.